Safety of anacetrapib in patients with or at high risk for coronary heart disease Academic Article uri icon

Overview

MeSH Major

  • Anticholesteremic Agents
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Coronary Disease
  • Oxazolidinones

abstract

  • Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. (Funded by Merck Research Laboratories; ClinicalTrials.gov number, NCT00685776.).

publication date

  • December 16, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1009744

PubMed ID

  • 21082868

Additional Document Info

start page

  • 2406

end page

  • 15

volume

  • 363

number

  • 25